Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
Publication
, Journal Article
Cosler, LE; Lyman, GH
Published in: Cancer Invest
December 2009
Duke Scholars
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
December 2009
Volume
27
Issue
10
Start / End Page
953 / 959
Location
England
Related Subject Headings
- Treatment Outcome
- Time Factors
- Risk Assessment
- Reproducibility of Results
- Receptors, Estrogen
- Quality-Adjusted Life Years
- Predictive Value of Tests
- Pharmacogenetics
- Patient Selection
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Cosler, L. E., & Lyman, G. H. (2009). Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest, 27(10), 953–959. https://doi.org/10.3109/07357900903275217
Cosler, Leon E., and Gary H. Lyman. “Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.” Cancer Invest 27, no. 10 (December 2009): 953–59. https://doi.org/10.3109/07357900903275217.
Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest. 2009 Dec;27(10):953–9.
Cosler, Leon E., and Gary H. Lyman. “Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.” Cancer Invest, vol. 27, no. 10, Dec. 2009, pp. 953–59. Pubmed, doi:10.3109/07357900903275217.
Cosler LE, Lyman GH. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest. 2009 Dec;27(10):953–959.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
December 2009
Volume
27
Issue
10
Start / End Page
953 / 959
Location
England
Related Subject Headings
- Treatment Outcome
- Time Factors
- Risk Assessment
- Reproducibility of Results
- Receptors, Estrogen
- Quality-Adjusted Life Years
- Predictive Value of Tests
- Pharmacogenetics
- Patient Selection
- Oncology & Carcinogenesis